SCHEMBL3018581

SCHEMBL3018581

O=S(=O)(c1ccc(CBr)cc1)N1CCN(c2nc(Cc3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
ALDH1A1 P00352 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
POLB P06746 2/20 0.45
LSS P48449 3/20 0.45
KDM4E B2RXH2 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
MAPT P10636 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
LMNA P02545 2/20 0.42
HSD17B10 Q99714 1/20 0.42
ATM Q13315 1/20 0.41
MAPK1 P28482 1/20 0.41
USP2 O75604 1/20 0.41
PKM P14618 1/20 0.41
GBA1 P04062 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HSD11B1 P28845 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007797 0.95 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1L3MBTL1POLBLSS
SCHEMBL3019185 0.92 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1L3MBTL1POLBLSS
SCHEMBL3020344 0.92 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1L3MBTL1POLBLSS
SCHEMBL3014736 0.91 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1L3MBTL1KDM4ENPSR1
SCHEMBL3009212 0.90 POLB (0.45) SMN1; SMN2ALDH1A1L3MBTL1POLBLSS
SCHEMBL3008811 0.90 THRB (0.47) SMN1; SMN2ALDH1A1L3MBTL1POLBLSS
SCHEMBL3015956 0.90 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1L3MBTL1POLBLMNA
SCHEMBL3010733 0.90 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1L3MBTL1POLBLSS
SCHEMBL3008181 0.90 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1L3MBTL1KDM4ENPSR1
SCHEMBL3018793 0.90 ALDH1A1 (0.60) SMN1; SMN2ALDH1A1L3MBTL1POLBLSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.